CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
揭示胶质母细胞瘤的免疫抑制微环境及治疗进展
英文原题：Unraveling the immunosuppressive microenvironment of glioblastoma and advancements in treatment.
查看英文原题
Unraveling the immunosuppressive microenvironment of glioblastoma and advancements in treatment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胶质母细胞瘤是最常见且侵袭性最强的原发性脑肿瘤，其免疫抑制性肿瘤微环境（TME）使其成为肿瘤学领域的一项重大挑战。本综述总结TME内免疫细胞与细胞因子之间的复杂相互作用及其对免疫逃逸和肿瘤进展的影响，并重点阐述这些组分之间的协同交流如何塑造治疗易感性。此外，本文介绍免疫检查点抑制剂、CAR-T 细胞治疗、NK细胞治疗、溶瘤病毒及疫苗策略等免疫治疗的最新进展。尽管临床前和临床研究结果令人鼓舞，克服免疫抑制性TME仍是关键难题。本综述强调，靶向TME有望改善胶质母细胞瘤的治疗结局。
展开英文摘要原文
Glioblastoma, the most common and aggressive primary brain tumor, remains a significant challenge in oncology due to its immunosuppressive tumor microenvironment (TME). This review summarizes the complex interplay of immune cells and cytokines within the TME, which contribute to immune evasion and tumor progression.
We further emphasize the synergistic crosstalk among these components and how it shapes therapeutic vulnerability. Besides, we highlight recent advancements in immunotherapy, including immune checkpoint inhibitors, CAR-T cell therapy, NK cell therapy, oncolytic viruses, and vaccine-based strategies. Despite promising preclinical and clinical results, overcoming the immunosuppressive TME remains a critical hurdle. This review underscores the potential of targeting the TME to enhance therapeutic outcomes in glioblastoma.
论文信息
- 作者
- Jiang D、Li Y
- 单位
- Department of Neurosurgery, The First Hospital of Jilin University, Changchun, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in immunology2025
- 原文标识
- PubMed 40443668 · DOI 10.3389/fimmu.2025.1590781
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →